Compare Citigroup Inc. (C) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs IDEXX Laboratories, Inc. — how do they compare? Citigroup Inc. trades at $137.62 (market cap $227.75B), while IDEXX Laboratories, Inc. trades at $571.44 (market cap $46.22B). The key difference: Citigroup Inc. is far larger — about 4.9× IDEXX Laboratories, Inc.'s market cap, and Citigroup Inc. pays a 1.97% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| C | IDXX | |
|---|---|---|
Market Cap | $227.75B | $46.22B |
Sector | Financials | Health |
52-Week High | $145.67 | $766.68 |
52-Week Low | $92.59 | $526.44 |
Dividend Yield | 1.97% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $137.78, up 1.89% today, with a bullish technical signal from moving averages and a consensus analyst price target of $154.38. Recent Q2 2026 earnings beat expectations with EPS of $3.15 versus $2.72 expected, while revenue reached a decade high. The company is actively hiring senior bankers and launching digital trade solutions, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and a 59% analyst buy rating, but risks include volatile cash flows from operations and high leverage. The stock offers potential upside to the price target, with investor focus on execution of the medium-term ROTCE target of 14-15%.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
